New insider activity at Benitec Biopharma ( (BNTC) ) has taken place on April 3, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Suvretta Capital Management, LLC has made a significant investment in Benitec Biopharma by purchasing 16,497 shares of the company’s stock, amounting to a total value of $211,736.
Recent Updates on BNTC stock
In the last 24 hours, Benitec Biopharma has seen significant developments, primarily driven by the announcement of positive interim results from its BB-301 Phase 1b/2a study. The study, presented at the 2025 Muscular Dystrophy Association Conference, demonstrated substantial improvements in swallowing function for subjects with Oculopharyngeal Muscular Dystrophy (OPMD), achieving clinically normal swallowing profiles and reducing dysphagic symptoms. These promising results have reinforced the company’s position in the gene therapy market, potentially influencing stock ratings positively. Additionally, Benitec announced the pricing of its underwritten and registered direct offerings, expected to raise approximately $30 million, which will be used to further develop its product candidate programs and for general corporate purposes. These developments have likely contributed to recent stock price movements and analyst interest.
More about Benitec Biopharma
YTD Price Performance: -0.50%
Average Trading Volume: 40,547
Technical Sentiment Signal: Sell
Current Market Cap: $331.7M